Literature DB >> 20592305

24-hour ambulatory blood pressure in the ACCOMPLISH trial.

Kenneth A Jamerson, George L Bakris, Michael A Weber.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20592305     DOI: 10.1056/NEJMc1001410

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

Review 1.  Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic.

Authors:  Wanpen Vongpatanasin
Journal:  Curr Opin Cardiol       Date:  2015-07       Impact factor: 2.161

Review 2.  Dihydropyridine calcium channel blockers and renal disease.

Authors:  Nicolás R Robles; Francesco Fici; Guido Grassi
Journal:  Hypertens Res       Date:  2016-07-14       Impact factor: 3.872

3.  Differential effectiveness of ARB plus CCB therapy and high-dose ARB therapy in high-risk elderly hypertensive patients: subanalysis of the OSCAR study.

Authors:  Shokei Kim-Mitsuyama; Hisao Ogawa; Kunihiko Matsui; Tomio Jinnouchi; Hideaki Jinnouchi; Kikuo Arakawa
Journal:  Hypertens Res       Date:  2014-12-04       Impact factor: 3.872

Review 4.  Role of ambulatory blood pressure monitoring in hypertension and diabetes.

Authors:  Colleen Flynn; George L Bakris
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

Review 5.  The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.

Authors:  James Brian Byrd; George Bakris; Kenneth Jamerson
Journal:  Curr Hypertens Rep       Date:  2014-03       Impact factor: 5.369

6.  Commentary in support of a highly effective hypertension treatment algorithm.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-08-07       Impact factor: 3.738

Review 7.  What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Authors:  Samir G Mallat
Journal:  Cardiovasc Diabetol       Date:  2012-04-10       Impact factor: 9.951

8.  Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.

Authors:  Robert D Brook; Niko Kaciroti; George Bakris; Björn Dahlöf; Bertram Pitt; Eric Velazquez; Michael Weber; Dion H Zappe; Tsushung Hau; Kenneth A Jamerson
Journal:  J Am Heart Assoc       Date:  2018-01-04       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.